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3-iodothyronamine (T1AM) is an endogenous amine, that has been detected in many
rodent tissues, and in human blood. It has been hypothesized to derive from thyroid
hormone metabolism, but this hypothesis still requires validation. T1AM is not a
ligand for nuclear thyroid hormone receptors, but stimulates with nanomolar affinity
trace amine-associated receptor 1 (TAAR1), a G protein-coupled membrane receptor.
With a lower affinity it interacts with alpha2A adrenergic receptors. Additional targets
are represented by apolipoprotein B100, mitochondrial ATP synthase, and membrane
monoamine transporters, but the functional relevance of these interactions is still
uncertain. Among the effects reported after administration of exogenous T1AM to
experimental animals, metabolic and neurological responses deserve special attention,
because they were obtained at low dosages, which increased endogenous tissue
concentration by about one order of magnitude. Systemic T1AM administration favored
fatty acid over glucose catabolism, increased ketogenesis and increased blood glucose.
Similar responses were elicited by intracerebral infusion, which inhibited insulin secretion
and stimulated glucagon secretion. However, T1AM administration increased ketogenesis
and gluconeogenesis also in hepatic cell lines and in perfused liver preparations, providing
evidence for a peripheral action, as well. In the central nervous system, T1AM behaved as
a neuromodulator, affecting adrenergic and/or histaminergic neurons. Intracerebral T1AM
administration favored learning and memory, modulated sleep and feeding, and decreased
the pain threshold. In conclusion T1AM should be considered as a component of thyroid
hormone signaling and might play a significant physiological and/or pathophysiological
role. T1AM analogs have already been synthetized and their therapeutical potential is
currently under investigation. 3-iodothyronamine (T1AM) is a biogenic amine whose
structure is closely related to that of thyroid hormone (3,5,3′-triiodothyronine, or T3). The
differences with T3 are the absence of the carboxylate group and the substitution of
iodine with hydrogen in 5 and 3′ positions (Figure 1). In this paper we will review the
evidence supporting the hypothesis that T1AM is a chemical messenger, namely that it
is an endogenous substance able to interact with specific receptors producing significant
functional effects. Special emphasis will be placed on neurological and metabolic effects,
which are likely to have physiological and pathophysiological importance.
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DISTRIBUTION AND METABOLISM OF T1AM
The gold standard technique for detecting T1AM is represented
by mass spectrometry, coupled to an appropriate separation tech-
nique, usually HPLC. While the initial reports of endogenous
T1AM in brain (Scanlan et al., 2004), heart (Chiellini et al.,
2007), and blood (Braulke et al., 2008) were admittedly non-
quantitative, subsequent technical improvements allowed the
assay of T1AM in virtually every tissue in rodents (Saba et al.,
2010), as well as in human blood (Galli et al., 2012). Tissue
concentrations were found to be on the order of 1–90 pmol/g,
and the highest values were detected in liver, brain, and muscle
(Saba et al., 2010). The presence of endogenous T1AM at this
concentration range has been subsequently confirmed in liver
(Hackenmueller et al., 2012; Ghelardoni et al., 2014) and brain
(Musilli et al., 2014).
In serum T1AMwas measured at a concentration on the order
of 0.2–0.3 nM both in rat and in human, and so it was signifi-
cantly lower than tissue concentration. In another investigation
T1AM was not detected in blood (Ackermans et al., 2010), but
in that study a different preparation procedure was used and
method sensitivity was probably too low (0.25 nM) to get posi-
tive results. On the other hand the presence of T1AM in human
blood was confirmed with a chemiluminescence immunoassay
(Hoefig et al., 2011), and its concentration was estimated to be
much higher, namely 66 nM. While it has been hypothesized
that the immunological assay may detect a fraction of T1AM
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FIGURE 1 | Chemical structures of 3,5,3′-triiodothyronine (T3),endogenous thyronamines (T1AM–T0AM) and synthetic analogs.
which is not extracted by the preparation procedure used for
mass spectrometry assays, an alternative explanation of this dis-
crepancy is the subsequent observation that T1AM binds with
high affinity to the plasma protein apoB-100 (Roy et al., 2012
see below). In fact the immunological assay was a competition
assay in which T1AM labeled with horseradish peroxidase was
used as a reporter and calibration curves were not obtained
in whole serum (Hoefig et al., 2011). Therefore, binding of
labeled T1AM to apoB-100 may have caused overestimation of
endogenous T1AM.
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Experiments in which cell cultures were exposed to exoge-
nous T1AM, or isolated organs were perfused with exogenous
T1AM, confirmed that T1AM is accumulated by many different
cells types, including hepatocytes, cardiomyocytes, and thyrocytes
(Saba et al., 2010; Agretti et al., 2011; Ghelardoni et al., 2014),
although the molecular identity of the T1AM transporter(s) still
remains to be clarified (Ianculescu et al., 2009; Saba et al., 2010).
Consistently, radiolabeled T1AM reached virtually every organ
after intravenous injection (Chiellini et al., 2012; Lee et al., 2013).
Acute uptake prevailed in liver, kidney, stomach, and intestine,
while after 24 hmost residual T1AMwas detected in liver, muscle,
and adipose tissue.
The close chemical similarity with T3 induced to speculate
that T1AM may be synthetized from the T3 through decarboxy-
lation and deiodination (Scanlan et al., 2004; Ianculescu and
Scanlan, 2010; Piehl et al., 2011). However, only trace amounts
of T1AM were produced in cardiomyocytes exposed to T3 (Saba
et al., 2010), while administration of deuterated T4 was not asso-
ciated with detection of deuterated T1AM in the liver of mice
treated with perchlorate and metimazole (Hackenmueller et al.,
2012). In human blood, a significant correlation between T3
and T1AM was observed when these substances were assayed by
mass spectrometry (Galli et al., 2012), while in thyroidectomized
patients treated with synthetic T4 normal serum T1AM values
were detected by chemiluminescence immunoassay, supporting
the hypothesis that T1AM may be an extrathyroidal metabo-
lite of thyroid hormone (Hoefig et al., 2011). Therefore, the
biosynthetic pathway responsible for T1AM production is still
uncertain.
Tissue T1AM metabolism includes oxidative deamination
to 3-iodothyroacetic acid, deiodination to thyronamine, N-
acetylation and esterification with sulfate or glucoronate (Pietsch
et al., 2007; Piehl et al., 2008; Wood et al., 2009; Saba et al., 2010;
Agretti et al., 2011; Hackenmueller and Scanlan, 2012). Either
T1AM or its catabolites undergo biliary and urinary excretion,
as shown by the observations performed after administration of
radiolabeled T1AM (Chiellini et al., 2012; Lee et al., 2013).
T1AM RECEPTORS AND BINDING SITES
T1AM is not a ligand for nuclear thyroid hormone receptors,
but it was found to stimulate with high affinity trace-amine
associated receptor 1 (TAAR1), a G protein-coupled membrane
receptor (Scanlan et al., 2004). TAAR1 was identified in 2001 on
the basis of its affinity for the so-called trace amines, namely
β-phenylethylamine, p-tyramine, triptamine, and octopamine
(Borowsky et al., 2001; Bunzow et al., 2001; Grandy, 2007). Nine
different TAAR subtypes exist, and they are widely expressed in
several tissues (Zucchi et al., 2006).
So far investigations on the physiological role of TAARs
have focused on the central nervous system effects of TAAR1,
which has been hypothesized to act as a physiological
regulator of monoaminergic neurotransmission. TAAR1 is
expressed in several brain areas, particularly the limbic
regions and nuclei containing monoaminergic cells (Lindemann
et al., 2008). In mouse, dopaminergic neuron firing in the
ventral tegmental area was modulated by p-tyramine. This
effect was lost in TAAR1 knockout mice (Lindemann et al.,
2008) and inhibited byN-(3-ethoxy-phenyl)-4-pyrrolidin-1-yl-3-
trifluoromethyl-benzamide (EPPTB), a selective TAAR1 antago-
nist (Bradaia et al., 2009). In addition, type 2 dopamine receptor
(D2R) antagonists enhanced TAAR1-mediated increase in cAMP,
possibly by disrupting TAAR1-D2R interaction (Espinoza et al.,
2011). Since D2R is the main target of antipsychotic drugs
such as haloperidol (Strange, 2001), the observed functional
TAAR1-D2R interaction might have potential therapeutic impli-
cations for dopamine-related disorders (Revel et al., 2011). It
has also been reported that TAAR1 is a target of psychotropic
agents like amphetamine, methamphetamine, 3,4-methylene-
dioxymetamphetamine (MDMA, known as “ecstasy”), and d-
lysergic acid diethylamide (Bunzow et al., 2001), suggesting a
role in neuropsychiatric disorders. Interestingly, human TAAR
genes are clustered on the long arm of chromosome 6, in
a region which is consistently associated with schizophrenia
or bipolar affective disorder in linkage studies (reviewed by
Zucchi et al., 2006).
Using cell cultures expressing heterologous TAAR1, T1AMwas
found to activate rat and mouse TAAR1, inducing cAMP pro-
duction with EC50 of 14 and 112 nM, respectively (Scanlan et al.,
2004). In thesemodels T1AMwasmore potent than all other trace
amines. Preliminary evidence that T1AM interacts with TAAR5
has been reported (Mühlhaus et al., 2013), and TAAR8 has also
been suggested as a potential target, on the basis of the pharmaco-
logical effects produced in the isolated rat heart (Frascarelli et al.,
2008).
TAAR1 and possibly other TAARs represent the most likely
endogenous receptor(s) for T1AM. However, receptor antago-
nists and knockout models are available only for TAAR1, and
they have not been extensively used in experimental investiga-
tions. Therefore, the role of specific TAARs in the response to
T1AM remains largely speculative, and the underlying trans-
duction pathways also require further investigations. Apart from
TAARs, additional binding sites for T1AM may exist, since the
comparison between tissue T1AM concentration and tissue TAAR
expression revealed a clear mismatch (Chiellini et al., 2012). As
a matter of fact, several candidates have been identified and are
listed below. In general, the functional consequences of T1AM
binding to these targets, if any, are still uncertain, and will be
discussed more extensively in the subsequent sections.
Other G protein-coupled receptors might bind T1AM,
although with a lower affinity than TAAR1. In particular, in COS7
cells transfected with human ormouse alpha 2A adrenergic recep-
tor (α2A), Ki values in the low micromolar range were obtained
(Regard et al., 2007).
The plasma protein apo-B100, a component of VLDL and LDL
lipoproteins, binds T1AM with a KD of 17 nM (Roy et al., 2012).
This is the likely reason for the difficulty in extracting T1AM from
blood samples, and for the discrepancies reported with serum
T1AM assays, as discussed above. The functional implications of
this interaction are uncertain, since no evidence that T1AM may
modify lipoprotein function has been reported so far.
Another molecular target appears to exist in mitochon-
dria, since T1AM modulated the activity of sub-mitochondrial
particles and soluble F1-ATPase (Cumero et al., 2012). Functional
and biochemical data suggested the existence of a high affinity
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binding site (affinity on the order of 50 nM), which prevents
the interaction between the ATP synthase and its physiological
inhibitor IF1, and a low affinity binding site (IC50 = 28μM),
through which T1AM reduces enzyme activity. Consistent with
these findings, T1AM has been reported to reduce oxygen con-
sumption and increase hydrogen peroxide release in rat liver
mitochondria (Venditti et al., 2011).
At concentrations in the low micromolar range, T1AM
interfered with monoamine transporters, namely norpinephrine
transporter, dopamine transporter and vesicular monoamine
transporter 2 (Snead et al., 2007). Both competitive and non-
competitive mechanisms contributed to the inhibition since
T1AM increased the Km and decreased the Vmax of each trans-
porter. Interaction with these targets might inhibit dopamine and
norepinephrine reuptake as well as their transport into synaptic
vesicles. It has also been reported that micromolar T1AM dis-
placed T3 and thyroxine (T4) from their membrane transporters,
namely monocarboxylate transporter 8 (MCT8), organic anion
transporting polypeptide 1A2 (OATP1A2), and organic anion
transporting polypeptide 1C1 (OATP1C1) (Ianculescu et al.,
2009).
METABOLIC EFFECTS OF T1AM
The effects that were originally reported after the administra-
tion of exogenous T1AM to rodents (50mg/Kg i.e., 128μmol/Kg
i.p.) included transient decrease in body temperature and reduc-
tion of cardiac inotropic and chronotropic state (Scanlan et al.,
2004; Chiellini et al., 2007). The former effect is not mediated by
TAAR1, since it was reproduced in TAAR1 knockout mice (Panas
et al., 2010), and it may be related to the inhibitory effect of
mitochondrial function, which has been described above. Cardiac
effects have been attributed to the modulation of ionic home-
ostasis, namely to a reduction of sarcoplasmic reticulum calcium
release and an inhibition of potassium currents, particularly tran-
sient outward current and Ik1 background current (Ghelardoni
et al., 2009). The transduction pathway probably involves specific
tyrosine kinases and/or phosphatases (Chiellini et al., 2007) and
pharmacological evidence is consistent with the hypothesis that
the receptor triggering this pathway belongs to the TAAR fam-
ily, whose major component in rat heart appears to be TAAR8
(Frascarelli et al., 2008).
In the isolated rat heart preparation, dose-response curves
were obtained, and the IC50 for T1AM was found to be on the
order of 20–40μM, i.e., substantially higher than average tissue
levels, which are in the range of a few picomoles per g. Thus,
these actions are unlikely to be physiological, although they might
be exploited pharmacologically, since exogenous T1AM protected
the myocardium from ischemia-reperfusion injury (Frascarelli
et al., 2011). Central nervous system protection was also reported
in a stroke model, and attributed to hypothermia (Doyle et al.,
2007).
On the other hand, recent investigations have described
metabolic and neurological effects of T1AM, occurring at rela-
tively low dosages. Therefore, regulation of metabolic homeosta-
sis and of central nervous system function appear to be the best
candidates in the search for the physiological effects of T1AM, and
they will be reviewed more extensively.
Acute metabolic responses to systemic (intraperitoneal)
administration of T1AM in Siberian hamster ormouse (50mg/Kg
i.e., 128μmol/Kg) included a reduction in respiratory quo-
tient from ∼0.90 to ∼0.70 (Braulke et al., 2008), indicating a
shift in metabolic pathways from carbohydrate to lipid oxida-
tion. Consistent with these observations, T1AM treatment caused
ketonuria and a significant loss of body fat. Both in mouse and
in rat, the same dose of T1AM also increased plasma glucose,
and this effect was attributed to hormonal changes, since inhi-
bition of insulin secretion and stimulation of glucagon secretion
were detected (Regard et al., 2007; Klieverik et al., 2009). The use
of transgenic mouse lacking α2A, and experiments performed in
pancreatic islets with Gi protein modulators, showed a biphasic
effect of T1AM on insulin secretion, namely stimulation through
TAAR1 and inhibition through α2A, the latter prevailing under
physiological conditions (Regard et al., 2007).
The results discussed above were obtained using pharma-
cological dosages of T1AM, namely 128μmol/Kg in vivo and
10μM in vitro. However, metabolic responses, particularly
increased plasma glucose and increased plasma glucagon, were
also elicited by i.c.v. infusion withmuch lower dosages (0.5mg/Kg
i.e., 1.28μmol/Kg), suggesting a neuroendocrine action on the
hypothalamic-pituitary-adrenal axis, which is a recently identi-
fied target for several hormones, including insulin, glucocorti-
coids and thyroid hormone (Fliers et al., 2010). The potency of
T1AM turned out to be even higher than initially thought, since
in subsequent investigations plasma glucose was increased after
i.c.v. injection of doses as low as 3.3 nmol/Kg (Manni et al., 2012)
or 0.3 nmol/Kg (Manni et al., 2013). In the latter study brain
T1AM was determined, and it was observed that effective doses
increased endogenous T1AM concentration by about one order
of magnitude (34-fold with 3.3 nmol/Kg T1AM).
However, the possibility of a peripheral, hormone-
independent action should not be ruled out, since T1AM
administration (at 0.5–1μM concentration) was able to increase
ketone body production and to stimulate gluconeogenesis in
hepatic cell lines and in perfused liver preparations (Ghelardoni
et al., 2014).
Recently, Haviland et al. (2013) used a combination of ana-
lytical techniques to explore the metabolic effect of prolonged
treatment with T1AM (10mg/Kg i.e., 26μmol/Kg i.p., for 8 days)
in a spontaneously obese mouse model. Breath carbon isotope
ratio (13CO2/12CO2, or δ13C value) was monitored continuously
by cavity ring down spectroscopy (CRDS), and plasma sam-
ples were collected and analyzed by nuclear magnetic resonance
(NMR). CRDS is a non-invasive technique that can be used
to assess lipid vs. carbohydrate/protein oxidation in real-time:
lipids are enriched in the lighter isotope (probably because of
isotopic fractionation during the pyruvate dehydrogenase reac-
tion), so during lipolysis more 12CO2 is generated, resulting in
a lower δ13C value (De Niro and Epstein, 1977; Schöller et al.,
1984). Breath δ13C declined shortly after T1AM injection, and
NMR metabolomics confirmed the increase in lipid utilization,
as revealed by elevation in plasma 3-hydroxybutyrate concentra-
tion. Increased lipolysis was independent of food consumption
and it was associated with weight loss (−8.2% of initial body
weight after 8 days of treatment). The effect was persistent,
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since 2 weeks after discontinuation of T1AM treatment mice
regained only 1.8% of the lost weight. In an ongoing investiga-
tion (Chiellini et al., 2013) it has been ascertained that lipolysis
and weight loss induced by 26μmol/Kg T1AM in mice are
not associated with increased plasma glucose, suggesting that
lipid metabolism is a more sensitive target than carbohydrate
metabolism.
These long-term effects are likely related to modulation of
gene expression, since T1AM significantly modified the expres-
sion of over 350 genes in adipose tissue and over 100 genes
in liver, in a direction consistent with the observed metabolic
changes (Mariotti et al., 2014). Modulated genes included sev-
eral members of the sirtuin family and genes playing established
roles in lipolysis, beta-oxidation, adipogenesis and lipoprotein
metabolism.
The molecular mechanisms underlying acute and chronic
metabolic effects remain to be determined, but T1AM-triggered
pathway(s) may be clinically relevant. In fact, in a small clinical
series serum T1AM concentration was found to be significantly
increased in type II diabetes, and T1AM levels were significantly
correlated with glycated hemoglobin (Galli et al., 2012).
In general, the effects which were originally reported for
T1AM, namely hypothermia and cardiac depression, were oppo-
site to those produced by thyroid hormone, so T1AMwas initially
viewed as a sort of feedback effector of thyroid signaling (Liggett,
2004). However, its metabolic effects (summarized in Table 1) are
to a large extent synergic with the response to thyroid hormone,
which is also known to induce a lipolytic effect (Mullur et al.,
2014).
Specific comparison between the transcriptional response
to T1AM and T3 revealed that the former produced signifi-
cant genomic effects, which were not reproduced by the latter
(Mariotti et al., 2014). Since T1AM is possibly synthetized from
T3, and T1AM may affect T3 transport and availability, it would
be interesting to evaluate if some effects traditionally attributed to
T3 may be directly or indirectly mediated by T1AM.
Table 1 | Metabolic and endocrine effects of T1AM.
• Increase in plasma glucose
• Reduced carbohydrate oxidation
• Increased gluconeogenesis
• Increased lipid oxidation
• Increased ketogenesis
• Decreased body weight in obese mice
Inhibition of insulin secretion*
Stimulation of glucagon secretion
The table summarizes the metabolic effects of T1AM. The reported effects have
been produced with acute or chronic administration of different concentrations
of T1AM (see text for further details). The effects are due to central effects
on the hypothalamic-pituitary-adrenal axis, but a peripheral component may also
exist.
*In pancreatic islets T1AM inhibited insulin secretion through α2A adrenore-
ceptor (α2AR) and stimulated insulin secretion throughtrace amine-associated
receptor 1(TAAR1), the former effect prevailing under physiological conditions.
Similar considerations apply to the neurological effects of
T1AM, which will be discussed in the more general context
of central nervous system modulation by the thyroid hormone
signaling system.
THYROID HORMONE AND THE CENTRAL NERVOUS SYSTEM:
THE CO-TRANSMITTER HYPOTHESIS
It is well known that thyroid hormone is necessary for nor-
mal brain development, and limited thyroid hormone availability
throughout fetal and neonatal periods results in mental retarda-
tion, deafness and ataxia (Schwartz, 1983). Its regulatory role in
the maintenance of adult brain function has not been completely
understood yet. Although it has long been known that mental
retardation is a result of hypothyroidism (Jackson, 1998), differ-
ent lines of research proved that significant reduction or increase
in T3 levels jeopardize both cognitive and mnemonic processes
when they are assessed in a clinical setting (Dugbartey, 1998) or
evaluated in animal models (Alzoubi et al., 2009; Taskin et al.,
2011).
Thyroid hormone can reach brain interstitial spaces through
two pathways, since it can either be transported across the brain-
blood barrier (BBB) or into the cerebral-spinal fluid (CSF) by
specific carriers (Cheng et al., 1994). In rodents these carriers are
mainly represented by MCT8, which transports both T3 and T4,
and OATP1C1, which shows a higher affinity for T4 and reverse
T3 (Sugiyama et al., 2003). MCT8 is expressed in choroid plexus
cells, brain capillaries, and neurons but it is not present in astro-
cytes. It mediates T4 and T3 passage through the BBB and into
the CSF (Heuer et al., 2005). OATP1C1 is present at the abluminal
side of brain micro-capillary endothelium and is localized in BBB
areas where acquaporin 4, a marker of astrocytes’ end-feet, is also
expressed. OATP1C1 is poorly expressed in adult primate BBB,
suggesting a primary role for MCT8 in humans (Ito et al., 2011).
Consistently, mutations in the MCT8 gene are associated with
the Allan-Herndon-Dudley syndrome, an X-linked disease char-
acterized by severe neurological involvement and reduced CSF T4
concentration (Kakinuma et al., 2005).
Even though blood-borne T3 can reach the brain tissue, nearly
80% of intracerebral T3 is produced locally from T4. Astrocytes
throughout the brain and tanycytes in the third ventricle are the
main site of conversion of T4 into T3, which is catalyzed by type II
iodothyronine 5-deiodinase (D2) (Guadaño-Ferraz et al., 1999).
At neuronal level, T3 can either cross the plasma membrane
through MCT8 or OATP1C1 to interact with nuclear receptors,
or modulate neuronal functions through non-genomic mecha-
nisms. T3 is then catabolized into 3,5-T2 by type III deiodinase
3 (D3), which is specifically expressed in neurons and is also
involved in the conversion of T4 into its inactive metabolite rT3
(Alkemade et al., 2005).
It has been speculated that in the brain iodothyronines may
act as co-transmitters and in particular that they may modulate
the response to the noradrenergic system (Gompf et al., 2010).
This hypothesis is based on different lines of evidence. First of
all, iodothyronines share considerable similarities with other neu-
rotransmitters in their effects and mechanisms of action during
brain development. Central neurotransmitters usually produce
appreciable effects on brain even before the full development
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of their specific circuitry. During this early phase they act as
growth factors and mitogens, stimulating cell growth and direct-
ing their migration (Lauder, 1983). Then, when neuronal pro-
cesses and synapses become widely available, they bind to their
specific receptors and behave as “conventional” neurotransmit-
ters. Likewise, iodothyronines show a differential neuronal distri-
bution in early and late development (Crutchfield and Dratman,
1983). During the first week of rat postnatal life, iodothyronines
accumulate in nuclear and cytosolic fractions and affect neuronal
maturation. For instance both hyper- and hypothyroidism have
been demonstrated to alter dendritic arborization of granule cells
in the hypothalamus of adult Wistar rats (Martí-Carbonell et al.,
2012), while T3 exerts a critical role in hippocampal cell prolif-
eration and granule cell precursor commitment (Remaud et al.,
2014). At a later stage the picture changes completely: there is a
geometrical growth in iodothyronine concentration at synapses
and nerve terminals, whereas the presence of iodothyronines
in the nucleus drops steadily, reaching a plateau 10 days after
birth.
In addition, while T3 has been located in almost all regions
in adult brain, reaching concentrations on the pmol/g order
(Dratman et al., 1983; Morreale de Escobar et al., 1985; Pinna
et al., 2002), iodothyronines concentrate specifically in the locus
coeruleus (LC) and in collateral centers involved in noradrener-
gic signaling (Dratman and Crutchfield, 1978; Dratman et al.,
1982). This is consistent with the peculiar location of LC, which
lies on the lateral floor of the fourth ventricle, a strategic site
favoring the uptake of T3 and T4, which are translocated through
the choroid plexus to enter the CSF. Furthermore, noradrenaline
was demonstrated to enhance the expression of D2 gene in
adult rat brain (Greer et al., 1991), providing a specific mech-
anism through which LC could concentrate T3 in its terminals.
Immunoistochemical studies confirmed that T3 is concentrated
in the regions that are integrated in the noradrenergic system,
where subcellular T3 distribution is quite peculiar: while in other
areas T3 is mainly identified in cell nuclei, in adrenergic neurons
it is located in the cell perikaria and in cell processes (Rozanov and
Dratman, 1996). The latter result is consistent with the hypothesis
that T3 is transported anterogradely through axonal processes in
LC neurons (Gordon et al., 1999). Treatment of rat LC terminals
with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), a
neurotoxin which specifically damages noradrenergic neurons,
produced the expected selective degeneration in noradrenergic
neurons, but also the loss of T3-immunoreactive cells in LC target
regions.
As a matter of fact, thyroid hormone can acutely affect neuron
firing. In Cornu Ammonis area 1 (CA1) T3 increased unit firing
rates and magnified neuronal firing induced by norepinephrine
stimulation (Caria et al., 2009). Furthermore, T3 injection in the
preoptic area of hypo- and eu-thyroid rats produced significant
changes in EEG patterns. In hypothyroid animals, administration
of 3μM of T3 reduced REM sleep, whereas higher doses (10μM)
induced an increase in the same parameter (Moffett et al., 2013).
In euthyroid rats, 1–3μM T3 induced an increase in REM sleep
and a significant decrease in slow-wave sleep duration (Martin
et al., 2013). The timing of these effects suggests the involvement
of non-genomic mechanisms.
Besides catecholamines, other neurotransmitters might be
affected by thyroid hormone. T3, T4, and rT3 decreased GABA
uptake in synaptosomes derived from rat brain (Mason et al.,
1987), while T3 inhibited GABAA-gated chloride currents in sev-
eral experimental models, namelyXenopus laevis oocytes (Chapell
et al., 1998), synaptosomes derived from rat hippocampal neu-
rons (Martin et al., 2004), and rat cultured hippocampal cells
(Puia and Losi, 2011). Inhibition of glutamate binding to type
NMDA receptor has been observed in the presence of thyroid
hormone (Oguro et al., 1989), although these effects occurred
at micromolar (i.e., non-physiological) concentrations. In rodent
models both hypo-and hyperthyroidism increased serotonin
turnover in the brainstem (Ito et al., 1977), which might result
in a robust activation of 5HT1A inhibitory autoreceptor in the
raphe nuclei (Bauer et al., 2002), in turn leading to reduced levels
of serotonin in the frontal cortex and decreased 5HT2A receptor
density in this area (Kulikov et al., 1999; Kulikov and Jeanningro,
2001). In this investigations only the frontal cortex was evaluated,
therefore it cannot be excluded that serotoninergic transmis-
sion may be affected by thyroid hormone levels also in other
neocortical areas. Indirect evidence of an action on the cholin-
ergic system is based on the observation that in a rodent model
sub-chronic and chronic T4 administration increased cholinergic
activity in the frontal cortex and hippocampus, which was associ-
ated with improved spatial memory abilities, as assessed through
the watermaze test (Smith et al., 2002).
NEUROLOGICAL EFFECTS OF T1AM
As detailed above, an intricate interplay appears to occur between
neuronal function, neurotransmitter signaling pathways and spe-
cific genomic or non-genomic actions of thyroid hormone. Since
1995, it has been hypothesized that a crucial modulatory role
could be played by thyroid hormone derivatives (Gordon et al.,
1995), and T1AM is now emerging as a possible modulator of
monoaminergic transmission and specifically of noradrenergic,
dopaminergic and histaminergic circuitries.
Electrophysiological recordings performed in LC showed that
the rate of discharge of adrenergic neurons was modified by
local application of T1AM (10μM) (Gompf et al., 2010). As
discussed above, there are reasons to believe that TAAR1, now
considered as a specific T1AM receptor, can interact with the
adrenergic system. Apart from TAAR1, additional T1AM targets
might be involved in neuromodulation. As already mentioned,
in synaptosomal fractions T1AM inihibited dopamine and nore-
pinephrine transporters (Snead et al., 2007). Since these two
transporters are responsible for dopamine and norepinephrine
reuptake into the presynaptic terminal, the expected down-
stream effects of T1AM are represented at first by accumula-
tion of extracellular monoamines, and afterwards by depletion
of neurotransmitter stores and reduction of neurotransmission.
Vesicular monoamine transporter 2 (VMAT2) is also subjected
to inhibition. This transporter is instrumental in the transloca-
tion of neurotransmitters (i.e., dopamine, norepinephrine, sero-
tonin, and histamine) from cytosol to synaptic vesicles, and so
T1AM could deplete neurotransmitters available for synaptic
transmission, although this hypothesis still needs experimental
validation.
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Another potential target is represented by α2A(Regard et al.,
2007). α2A plays a peculiar role in central neurotransmission,
since along with α2Dit is expressed as an inhibiting autorecep-
tor on noradrenergic presynaptic terminals and as a modulating
heteroreceptor in serotonergic, dopaminergic, and glutamatergic
neurons (Gilsbach and Hein, 2012). Cortical activation might
be another consequence of α2A activation: while it is widely
known that LC exerts an excitatory influence on the cerebral cor-
tex through α1-receptor activation (Papay et al., 2006), α2A is
also expressed at the cortical level (Blake et al., 1998), mainly in
inhibitory interneurons, so α2A stimulation induces disinhibition
of the cerebral cortex (Andrews and Lavin, 2006).
In line with these results, microinjections of T1AM in the pre-
optic region induced a significant reduction in non-REM sleep
(at doses of 1 and 3μg = 2.5 and 7.5 nmoles) and an increase
in low and theta frequencies in the power spectrum of EEG-
defined wakefulness (at a dose of 3μg = 7.5 nmoles) (James
et al., 2013). Notably, these effects closely mirrored the effects
of thyroid hormone administration. Consistent with these obser-
vations, i.c.v. injection of T1AM in a mouse model (at doses of
1.32 and 4μg/Kg = 3.3–10.2 nmol/Kg) produced a significant
increase in exploratory activity assessed through the hole-board
test (Manni et al., 2013). As it could be expected, the same results
on wakefulness and motor activity were produced by the injec-
tion of norepinephrine in the preoptic region of adult rat brain
(Emlen et al., 1972).
In addition to these effects, T1AM (1.32–4μg/Kg = 3.3–
10.2 nmol/Kg) induced pro-learning and anti-amnestic responses
when administered i.c.v. (Manni et al., 2013). In the object recog-
nition task mice showed significantly enhanced exploratory pref-
erence and curiosity for the novel object, which was retained after
24 h. The passive avoidance test confirmed that T1AM favored
learning both at 1 h and at 24 h after i.c.v. injection, and it
counteracted the amnestic effect of scopolamine. The response
to T1AM was antagonized by the monoamine oxidase inhibitor
chlorgyline, which is consistent with the hypothesis of an interac-
tion with the noradrenergic system. In fact, it is well known that
LC projections to the hippocampus are involved in both forma-
tion (Sullivan et al., 1994) and retrieval (Sara andDevauges, 1988)
of memories in rat models.
A recent study byMusilli et al. (2014) has suggested that T1AM
main oxidative metabolite, 3-iodothyroacetic acid (TA1), may
also play a role in the stimulation of memory acquisition, possibly
by activating a histaminergic system, since its effect was prevented
by H1 receptor antagonists. Interestingly, histamine is known to
modulate the synchronization of neuron burst in CA3, which is an
area of the hippocampus playing a central role in synaptic plastic-
ity and in the formation of memory traces (Buzsaki and Draguhn,
2004).
Other interactions between T1AM signaling and histamine cir-
cuitry have been identified. Histamine has been demonstrated
to modulate pain at the cortical and subcortical level, inducing
hyperalgesia at low doses throughH1 receptors (Malmberg-Aiello
et al., 1994; Galeotti et al., 2004). In line with these observa-
tions, i.c.v. injection of TA1 (0.4μg/Kg) reduced the threshold to
painful stimuli in mice subjected to the hot plate test, and the
effect was completely abolished when TA1 was co-administered
with histamine receptor antagonists and in mice lacking histidine
decarboxylase, the enzyme responsible for histamine synthesis
(Musilli et al., 2014).
T1AM has also important effects on the regulation of food
intake. Intracerebral T1AM injection induced significant alter-
ation in feeding behavior in fasting mice and in mice fed ad libi-
tum. In the latter group, when T1AM was administered either in
the arcuate nucleus (at doses of 0.12–1.2 nmol/Kg) or in cerebral
ventricles (at the dose of 1.2 nmol/kg), an orexigenic effect was
induced (Dhillo et al., 2009). It was also observed that exposure
of hypothalamic slices to T1AM in vitro induced neuropeptide
Y (NPY) release, suggesting that this potent orexigenic pep-
tide is involved in the hyperphagic effect. However, in fasting
mice a biphasic response was elicited by i.c.v. T1AM adminis-
tration, since low dosages (1.32μg/Kg = 3.3 nmol/Kg) produced
an anorexic effect while higher dosages (20μg/Kg = 51 nmol/Kg)
turned out to be orexigenic (Manni et al., 2012).
Effects of chronic treatment have also been reported. In a study
that was published only in abstract form, Hettinger et al. (2010)
observed that chronic systemic (i.p.) administration of T1AM (31
mg/Kg per day = 79μmol/Kg per day for 14 days) reduced food
intake in mice, while no change in food assumption was observed
at a lower dosage (10mg/kg per day = 26μmol/Kg per day for 8
days) by Haviland et al. (2013).
The mechanism of feeding modulation by T1AM is not
known, but a role for histamine cannot be excluded. In fact, his-
taminergic neurons form a network that is involved in the balance
of neuroendocrine and feeding inputs within the hypothalamus.
Histamine induces suppression of food intake when interact-
ing with the satiety center in the ventromedial hypothalamus
(Ookuma et al., 1993). On the other hand, i.c.v. injection of H3
histamine receptor antagonists induce suppression of food intake
(Cohn et al., 1973). Therefore, this dual action on feeding behav-
ior might be involved in the effects of T1AM and/or its catabolite
TA1 on food intake.
Most interestingly in the few investigations in which brain tis-
sue could be assayed to determine thyroid hormone and T1AM,
it was observed that after administration of effective T1AM
dosages (1.3μg/Kg = 3.3 nmol/Kg), average brain T1AM con-
centration increased by about one order of magnitude over the
baseline, while brain T3 and T4 concentrations were unchanged
(Manni et al., 2013). So, functional effects occurred at tissue
concentrations close to the physiological range. A summary of
the neurological effects which have been described after T1AM
administration is reported in Table 2.
EXPLOITING T1AM SIGNALING
The different functional effects of T1AM and the widespread
distribution of TAARs raise the hope that this novel signaling sys-
tem may be exploited in human therapeutics. A large number of
T1AM derivatives have already been synthesized and evaluated
as TAAR1 agonists. As shown in Figure 1, the first generation of
T1AM analogs (Hart et al., 2006) featured removal of the phe-
nol hydroxyl, an increase in the distance between the two aryl
rings, a change in the electronic and steric requirements on the
aryl ring distal to the amine functionality, alkylation or modifica-
tion of the amine, and replacement of the 3-iodo substituent with
an alkyl group. These analogs were evaluated using the cAMP
accumulation assay in cells stably expressing either rat or mouse
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Table 2 | Neurological effects of T1AM.
Electrophysiological effects on the Locus Coeruleus:
• Increased neuronal firing
EEG patterns (microinjection in the preoptic region):
• Reduction in nREM sleep
Behavior (i.c.v. administration):
• Increase in exploratory activity
Memory (i.c.v. administration):
• Prolearning and antiamnestic effect
Pain (i.c.v. administration):
• Decreased pain threshold to hot stimuli
Food intake (acute central administration):
• In ad libitum fed mice: orexigenic effect
• In fasting mice: biphasic effect, with anorexic properties at low
doses and orexigenic effects at higher doses
Food intake (chronic peripheral administration, i.p.):
• Anorexic effect
The table summarizes the neurological effects of T1AM. The reported effects
have been produced with acute or chronic administration of different concen-
trations of T1AM (see text for further details). Abbreviations: EEG, electroen-
cephalography; i.c.v., intracerebroventricular; i.p., intraperitoneal.
TAAR1 (rTAAR1 and mTAAR1). Analysis of the results summa-
rized in Table 3 suggests the following requirements for TAAR
activation:
(i) A basic amino group at Cα is required. In the case of com-
pound 72, where the amine was replaced with a hydroxyl, no
TAAR1 activation was observed.
(ii) Monomethylation of the amine can be beneficial (com-
pounds 62 and 85) although larger alkyl groups (compounds
64-66) and bis-alkylation (compound 67) are deleterious.
(iii) mTAAR1 and rTAAR1 differ with respect to their tolerance of
changes in the diaryl linker, both in length and in functional-
ity. In the case of rTAAR1 activation, derivatives 77, 91, and
92 were the most potent, while in the case of mTAAR1, the
most effective compounds were derivatives 85, 91, and 92.
(iv) Within the thyronamine scaffold, an iodine or methyl sub-
stituent at the 3-position is optimal. Derivative 77 with a
methyl group at the 3-position of the thyronamine scaffold
was nearly as potent as T1AM against both rTAAR1 and
mTAAR1.
(v) An H at the 4′-position vs OH is optimal (compound 91
was the most potent agonist of rTAAR1 and one of the most
potent at mTAAR1) and substituents larger than OH are
deleterious (compounds 93 and 97).
The most potent derivatives reported by Hart et al. (2006),
namely compounds 77, 85, 91, and 92, were also examined for
hypothermia induction in mice. When administered to mice at
a 50mg/kg dose, all derivatives induced significant hypothermia
within 60min and exhibited a hypothermic induction profile
analogous to T1AM. Derivative 91 was the most potent, and an
ED50 of 30μmol/kg was calculated.
On the basis of the report that TAAR1 can be activated
by phenethylamine analogs like amphetamines and ergolines
(Bunzow et al., 2001), an additional group of phenyltyramine
derivatives was devised and analyzed by Tan et al. (2007).
This investigation showed that the potency of thyronamines for
both rTAAR1 and mTAAR1 can be enhanced by incorporat-
ing appropriate functionalities in the ethylamine portion of the
phenoxyphenylethylamine scaffold. Even though rTAAR1 and
mTAAR1 are 93% similar, the two rodent receptors have differ-
ent structural preferences for this region of the scaffold, with
rTAAR1 favoring unsaturated hydrocarbon groups and mTAAR1
preferring functional groups that are polar and hydrogen-bond
acceptors. Analysis of single and double mutants of rat andmouse
TAAR1 (Tan et al., 2009) showed that key, non-conserved speci-
ficity determinant residues in transmembranes helices 4 and 7
within the ligand binding site appear to be the primary source
of the observed ligand preferences. In particular, residue 7.39
appears to dictate the specificity for a β-phenyl ring: a bulky
tyrosine residue at 7.39 in mTAAR1 sterically clashed with the
β-phenyl ring, whereas a smaller asparagine residue at the same
location in rTAAR1 was able to accommodate a β-phenyl moiety.
The lower potency of T1AM in mTAAR1 (EC50 = 112 nM) vs.
rTAAR1 (EC50 = 14 nM) appeared to be caused by the presence
of a tyrosine instead of a phenylalanine at residue 4.56. Despite
this species variability, transforming the inner ring of the phe-
noxyphenethylamine scaffold into a naphthyl group, as in com-
pound 24, was equally beneficial to both receptors, most likely
acting as an excellent isosteric replacement for the iodophenyl
inner ring of T1AM (Table 4).
A different approach has been followed by Hoffmann-La
Roche chemists, who have developed a novel series of imidazole
compounds that are potent and selective partial and full agonists
of the TAAR1 receptor (Galley et al., 2012; Revel et al., 2013).
In rodents, activation of TAAR1 by the full agonist RO5256390
and the partial agonist RO5263397 (Figure 1), blocked psychos-
timulant induced hyperactivity and produced a similar activation
pattern as the antipsychotic drug olanzapine. Notably, TAAR1
agonists do not induce catalepsy or weight gain; RO5263397 even
reduced haloperidol-induced catalepsy and prevented olanzapine
from increasing body weight and fat accumulation. In addi-
tion, TAAR1 activation promoted vigilance in rats and showed
pro-cognitive and antidepressant-like properties in rodent and
primate models (Revel et al., 2013).
Quite recently a preliminary report has described the synthe-
sis of T1AM analogs in which the two aromatic rings are linked
by a methylene group, the hydroxyl group (OH) at position 4′
has been replaced by an amino group (NH2), and the ethylamine
side chain at position 1 has been replaced by an oxy-ethylamine
side chain (Chiellini et al., 2014). Interestingly, these compounds
were effective on mouse TAAR1 but in functional experiments
they increased plasma glycemia and reduced cardiac output, i.e.,
they produced effects which are known not to be mediated by
TAAR1 (Regard et al., 2007; Frascarelli et al., 2008). These obser-
vations raise the possibility that different receptors systems may
be targeted by T1AM analogs and/or putative TAAR1 agonists.
CONCLUSIONS
In conclusion, T1AM is a novel chemical messenger, that inter-
acts with a specific G protein-coupled receptor, TAAR1, and
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Table 3 | Activity of first generation analogs of thyronamines on rTAAR1 and mTAAR1 (as reported by Hart et al., 2006).
Concentrations are expressed as nM.
Table 4 | Activity of naphethylamine (derivative 24) on rTAAR1 and
mTAAR1 (derived by Tan et al., 2007).
rTAAR1 mTAAR1
EC50± s.e.m. Emax± s.e.m. (%) EC50± s.e.m. Emax ± s.e.m. (%)
(nM) (nM)
26 ± 1 113 ± 5 101 ± 22 104 ± 3
possibly with other molecular targets. At tissue concentrations
close to the physiological range it produces significant metabolic
and neurological effects. From the metabolic side, it stimulates
lipid catabolism and induces in general anti-insulin responses;
from the neurological side, it has been reported to favor learning
and memory, modulate sleep and feeding, and decrease the pain
threshold. While available evidence suggests that T1AM should
be regarded as a neuromodulator, the molecular details of its
actions, and the underlying transduction pathways, remain to be
determined.
It has been suggested, although not yet formally demonstrated,
that T1AM is synthetized from T3, and some of its actions are
partly synergic with, but not identical to, the known metabolic
and neurological responses to thyroid hormone. So T1AMmight
be responsible for some effects traditionally attributed to thyroid
hormone itself, and should be viewed as a component of thyroid
hormone signaling. Exploring this novel aminergic system might
open new perspectives in the analysis of hormonal and neuroen-
docrine regulation of energy balance and behavior, and provide
new targets for potential therapeutic interventions in metabolic,
endocrine and neurological disease.
Critical research issues for the near future include clarifying
the role of TAAR1 vs other receptors in the response to T1AM
and dissecting the underlying transduction pathways. In order to
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confirm the physiological actions of T1AM, it is also essential
to reduce or abolish endogenous T1AM production by appro-
priate experimental interventions. The latter would require a
better understanding of the biochemical pathway(s) responsible
for T1AM synthesis.
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